Eculizumab has a meaningful effect on relapse in AQP4-IgG4+ neuromyelitis optica spectrum disorder (NMOSD) despite differences in standard of care between regions, according to an international research group.
Eculizumab has a meaningful effect on relapse in AQP4-IgG4+ neuromyelitis optica spectrum disorder (NMOSD) despite differences in standard of care between regions, according to an international research group.